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DISPATCHES

Human
Parvovirus 4 as
Potential Cause
of Encephalitis in
Children, India
Laura A. Benjamin, Penny Lewthwaite,
Ravi Vasanthapuram, Guoyan Zhao, Colin Sharp,
Peter Simmonds, David Wang, and Tom Solomon
To investigate whether uncharacterized infectious
agents were associated with neurologic disease, we
analyzed cerebrospinal fluid specimens from 12 children
with acute central nervous system infection. A highthroughput pyrosequencing screen detected human
parvovirus 4 DNA in cerebrospinal fluid of 2 children with
encephalitis of unknown etiology.

E

ncephalitis is a major cause of death and disability
globally. In Asia, Japanese encephalitis virus is the
most commonly recognized cause, with 30,000–50,000
cases and ≈10,000 deaths annually (1). However, for
most encephalitis cases, the cause is unknown, even with
comprehensive screening for recognized agents (1).
The advent of high-throughput sequencing technologies
enabled the direct characterization of microbial nucleic
acid from clinical samples and revolutionized the process
for identifying potential etiologic agents of disease. A
key feature is that the method is unbiased and can detect
any nonhost nucleic acid sequences present in a sample.
It has the potential to detect expected agents, known but
unexpected agents, and novel agents (2).
Human parvovirus 4 (PARV4) is a single-stranded
DNA virus first detected in 2005 (3). Infections with PARV4
are accompanied by acute viremia for several weeks (C.
Sharp et al., unpub. data), followed by seroconversion for
antibody and virus clearance. As observed with another
human parvovirus, parvovirus B19, there is long term
persistence of viral DNA sequences in several tissues but
not the brain (4). We describe 2 children in southern India
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with suspected encephalitis and high PARV4 levels in their
cerebrospinal fluid (CSF).
The Study
We obtained CSF from a cohort of children (<16 years
of age) hospitalized with a suspected acute central nervous
system (CNS) infection at the Vijayanagar Institute of
Medical Sciences, Bellary, India, October 2005–October
2007, as previously described (5). Suspected CNS infection
was defined as a febrile illness (for <2 weeks) and >1 of
the following signs or symptoms: severe headache, altered
mental status, seizures, or focal neurologic signs (6).
To investigate whether uncharacterized infectious
agents were associated with neurologic disease, we
obtained CSF specimens from 12 patients with acute
CNS infection (i.e., febrile illness with CSF leukocyte
count >5 cells/mm3 or protein >45 mg/dL). These patients
had negative diagnostic test results for pathogens known
to cause CNS infection in this region of India at the
time of investigation (e.g., Japanese encephalitis virus,
chikungunya virus, dengue fever virus, and Plasmodium
falciparum); in addition, CSF culture was performed and
no bacterial organisms were found (5). Total nucleic acid
was extracted from whole CSF and randomly amplified
as previously described with the modification that 6-nt
barcodes were added to the 5′ end of the primers used
for the amplification (7). The amplified materials were
pooled together and processed by using a high-throughput
pyrosequencing technique on a GS FLX Titanium Platform
(454 Life Sciences/Roche, Branford, CT, USA).
The raw sequence reads were deconvoluted on the basis
of the barcode and then processed through a standardized
bioinformatic pipeline (2). The sequences of interest were
then categorized into taxonomy groups based on the best
BLAST (www.ncbi.nlm.nih.gov/BLAST/) hit. For 2 of the
12 patients, patients VES085 and VES065, viral sequences
were detected in the CSF.
We identified 17 (92.6%–98.2% sequence identity)
distinct sequence reads in the CSF of patient VES085
and 6 (95.6%–98.9% sequence identity) distinct reads
from patient VES065 with pairwise identities based on
BLASTn alignment of each read to the reference genome
(GenBank accession no. EU175855.1). To verify the
results, we used PARV4-specific PCR primers to screen
all 12 original CSF samples as described (8). Only
samples from VES085 and VES065 were positive; all
other samples were negative by PCR.
PARV4 viral loads in the 2 CSF samples and the
corresponding serum sample from 1 patient collected
contemporaneously were semiquantified by limiting
dilution PCR by using primers on 5 replicate samples of
each dilution. The PCR conditions demonstrated single
copy sensitivity (data not shown), and endpoint titers
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Table 1. Clinical and laboratory characteristics of children with CSF positive for human parvovirus 4, India*
CSF
ID, date of Age,
Protein, Glucose,
illness
y
Clinical course
Outcome
PCR
WCC† mg/dL
mg/dL
4
59
32
VES085,
2
Prodomal illness for 12
Discharged
+
days; febrile with frequent against medical 1.5 x 107
2006 Jan
generalized convulsions
advice on day copies/mL
during first week of
18 after
admission
admission; CSF
examination on day 12 of
illness
VES065
3
Prodomal illness for 9
Recovered on
+
8
15
60
5
days; febrile, poor
day 14 with no
2005 Nov
3.2 x 10
appetite, and a
residual
copies/mL
generalized convulsion on
neurologic
deficit
day 9; CSF examination
on day 9 of illness

Serum
IgM
+

IgG


PCR
+
9
5.6 x 10
copies/mL

NA

NA

NA

*CSF, cerebrospinal fluid; ID, patient identification code; WCC, leukocyte count; Ig, immunoglobulin; +, positive; , negative; NA, not available.
†Leukocyte count differential 100% lymphocytes for each patient.

of 50% positivity were calculated by using the ReedMuench formula (8,9). Both the CSF and 1 serum sample
demonstrated high endpoint titers, indicating acute
infection and substantial virus spread into the CNS of the 2
patients (Table 1).
To genetically characterize PARV4 variants infecting
the patients, we generated overlapping sets of amplicons
spanning the complete genome of PARV4 from the 3
samples. No variation was seen between the CSF and
serum-derived sequences from VES085. The fully
assembled coding regions of the variants generated from
both patients were compared to previously described
PARV4 variants (n = 18 viral proteins 2/1 and n = 19
nonstructural sequences) (Table 2). Phylogenetic analysis
demonstrated that both variants belonged to genotype 2
(Figure). All sequences have been submitted to GenBank
(accession nos. HQ593530–HQ593532).
The serum sample was screened for immunoglobulin
(Ig) G and IgM PARV4-specific antibodies by using a
previously developed serologic assay for PARV4 antibodies
(10). The serum of VES085 was IgM positive and IgG
negative, consistent with an acute infection (Table 1).
Through serologic screening of age-matched
controls, we were able to largely rule out the possibility
that detection of PARV4 DNA in samples from 2 of the
12 patients was simply incidental to a high background

incidence of PARV4 infection in this age group. Although
published data on the duration of viremia in patients with
acute PARV4 infections has not been directly determined,
viral loads as found in the study patients are of relatively
short duration in other parvovirus infections (16 days for
viral loads >5,000 DNA copies/mL in the case of B19)
(11). Furthermore, through testing sequential samples
from persons exposed to PARV4, we have found no
persons with viremia duration of >6 weeks (C. Sharp et
al., unpub. data). Using the 6-week (maximum) estimate
and a background incidence of infection of 2.2% per year
(based on the detection of 4/41 seropositive children
with a mean age of 4.5 years), the likelihood of viremia
detection would be at most 0.25%, a figure consistent with
the actual measured absence of viremia detection in the
control cohort.
Conclusions
PARV4 is a recently identified virus found in human
blood and in a variety of tissues but with no known disease
association. In this study we detected PARV4 DNA in 2 of
12 CSF samples from patients with suspected encephalitis
of unknown cause in southern India. Unfortunately, no
samples were available from the wider cohort for further
testing. The presence of PARV4 DNA and IgM against
PARV4 in acute-phase serum from the 1 child with this

Table 2. Percent divergence of the nonstructural coding region of human PARV4–positive encephalitis patients VES065 and VES085,
compared with previously described PARV4 variants*
Genotype 3,
Genotype 2,
Genotype 1,
VES085 serum, VES085 CSF,
VES065 CSF,
aa (nt), n = 1
aa (nt), n = 7
aa (nt), n = 11
aa (nt), n = 1
aa (nt), n = 1
aa (nt), n = 1
Patient or genotype
VES065 CSF, n = 1
9.5 (3.5)
3.7 (1.5)
10.3 (3.7)
0.2 (0.0)
0.2 (0.0)
VES085 CSF, n = 1
9.4 (3.5)
3.6 (1.5)
10.2 (3.7)
0.0 (0.0)
VES085 serum, n = 1
9.4 (3.5)
3.6 (1.5)
10.2 (3.7)
Genotype 1, n = 11
8.0 (2.6)
9.3 (2.9)
0.9 (0.6)
Genotype 2, n = 7
8.6 (2.7)
1.8 (0.7)
Genotype 3, n = 1
*PARV4, human parvovirus 4; CSF, cerebrospinal fluid.
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PARV4 is primarily found in injection drug users
and persons who have received blood products; PARV4
is therefore presumed to be transmitted parenterally.
However, the risk for such transmission in the children
in our study was low, which supports the possibility of an
alternative route of transmission (8,12). HIV testing was
not available.
The use of high-throughput sequencing for identifying
an unexpected possible cause of CNS infection (PARV4)
is cutting edge; this technique’s utility also extends to a
recent identification of astrovirus in a case of encephalitis
(13). With the high seroprevalence of PARV4 infection
highlighted in recent reports (5%–37%), there is a clear
need to further assess the role of PARV4 in CNS infection
across the globe (14,15).

Figure. Phylogenetic analysis of (A) complete nonstructural (NS)
and (B) viral protein (VP) 1/VP 2 gene sequences of human
parvovirus 4 (PARV4) variants isolated from patients with
encephalitis of unknown etiology using 167 available sequences
from human PARV4 variants (genotypes 1–3). Blue, study sample;
red, genotype 1; orange, genotype 2; yellow, genotype 3. The
porcine hokovirus sequence (GenBank accession no. EU200671)
was used as an outgroup (not shown). The trees were constructed
by neighbor-joining of pairwise maximum-composite likelihood
corrected distances between nucleotide sequences; bootstrap
values ≈70% are shown. Scale bars represent an evolutionary
distance of 0.05.

sample available further supports the contention that this
was an acute infection.
Brain biopsy, the definitive investigation, was not
available at the time. More often than not, clinicians have
to rely on surrogate markers to diagnose encephalitis (e.g.,
CSF pleocytosis, febrile illness, and focal neurologic signs
in the right clinical context). It is more common to have
CSF pleocytosis than not, though of course there are well
characterized cases of CNS infection (e.g., dengue) with no
pleocytosis (6).
CSF erythrocyte count was not routinely measured in
this resource-limited setting. Although it is theoretically
possible the parvovirus detected in the CSF could have
reflected spillover from a blood-contaminated spinal tap,
there was no overt evidence of hemorrhagic CSF. The fact
that patient VES085 was febrile with a neurologic syndrome
and positive serum IgM, and patient VES065 had similar
clinical signs with high PARV4 viral CSF levels suggests
that they did indeed have a CNS infection.
1486

Acknowledgments
We thank members of the Wang Lab, the Washington
University pathogen discovery facility, and Ming-hua Li for their
help in performing the experiments; Mike Griffiths for assisting
with the expedient transport of sample materials to the United
States; Neil Hall for helpful discussions; and Peter Winstanley for
initially facilitating this study.
This project was supported in part by Wellcome Trust,
Burroughs Wellcome Fund, UK Medical Research Council, and
National Institutes of Health grant U54 AI057160 to the Midwest
Regional Centre of Excellence for Biodefense and Emerging
Infectious Disease Research.
Dr Benjamin is a Wellcome Trust clinical research fellow at
the University of Liverpool with an interest in neurology. She is
currently pursuing a PhD focusing on the role of infective agents
in brain disease.
References
1.

Solomon T, Thao TT, Lewthwaite P, Ooi MH, Kneen R, Dung NM,
et al. A cohort study to assess the new WHO Japanese encephalitis
surveillance standards. Bull World Health Organ. 2008;86:178–86.
doi:10.2471/BLT.07.043307
2. Finkbeiner SR, Li Y, Ruone S, Conrardy C, Gregoricus N, Toney D,
et al. Identification of a novel astrovirus (astrovirus VA1) associated
with an outbreak of acute gastroenteritis. J Virol. 2009;83:10836–9.
doi:10.1128/JVI.00998-09
3. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart
E. New DNA viruses identified in patients with acute viral infection
syndrome. J Virol. 2005;79:8230–6. doi:10.1128/JVI.79.13.82308236.2005
4. Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue
distribution, persistence, and molecular epidemiology of parvovirus
B19 and novel human parvoviruses PARV4 and human bocavirus. J
Infect Dis. 2007;195:1345–52. doi:10.1086/513280
5. Lewthwaite P, Vasanthapuram R, Osborne JC, Begum A, Plank JL,
Shankar MV, et al. Chikungunya virus and central nervous system
infections in children, India. Emerg Infect Dis. 2009;15:329–31.
doi:10.3201/eid1502.080902

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 8, August 2011

PARV4 in Children, India

6.

Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al. Neurological manifestations of dengue infection.
Lancet. 2000;355:1053–9. doi:10.1016/S0140-6736(00)02036-5
7. Wang D, Urisman A, Liu YT, Springer M, Ksiazek TG, Erdman DD,
et al. Viral discovery and sequence recovery using DNA microarrays. PLoS Biol. 2003;1:e2. doi:10.1371/journal.pbio.0000002
8. Sharp CP, LeBreton M, Kantola K, Nana A, Diffo Jle D, Djoko CF,
et al. Widespread infection with homologues of human parvoviruses
B19, PARV4, and human bocavirus of chimpanzees and gorillas in
the wild. J Virol. 2010;84:10289–96. doi:10.1128/JVI.01304-10
9. Reed LJMH. Simple method of estimating fifty per cent endpoints.
Am J Hyg. 1938;27:493–7.
10. Sharp CP, Lail A, Donfield S, Simmons R, Leen C, Klenerman P,
et al. High frequencies of exposure to the novel human parvovirus
PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:1119–
25. doi:10.1086/605646
11. Zaaijer HL, Koppelman MH, Farrington CP. Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect. 2004;132:1161–6.
doi:10.1017/S0950268804002730

12.

Panning M, Kobbe R, Vollbach S, Drexler JF, Adjei S, Adjei O, et
al. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg
Infect Dis. 2010;16:1143–6. doi:10.3201/eid1607.100025
13. Quan PL, Wagner TA, Briese T, Torgerson TR, Hornig M,
Tashmukhamedova A, et al. Astrovirus encephalitis in boy with Xlinked agammaglobulinemia. Emerg Infect Dis. 2010;16:918–25.
14. Sharp CP, Vermeulen M, Nebie Y, Djoko CF, LeBreton M, Tamoufe
U, et al. Changing epidemiology of human parvovirus 4 infection in
sub-Saharan Africa. Emerg Infect Dis. 2010;16:1605–7.
15. Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA. Novel parvovirus and related variant in human plasma. Emerg Infect Dis.
2006;12:151–4.
Address for correspondence: Tom Solomon, Brain Infections Group,
Institute of Infection and Globel Health, University of Liverpool, 8th Floor
Duncan Bldg, Daulby St, Liverpool L69 3GA, UK; email: tsolomon@
liverpool.ac.uk

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 8, August 2011

1487

